The estimated Net Worth of Christine Marie Utter is at least $5.66 Millón dollars as of 30 January 2024. Ms. Utter owns over 318 units of PTC Therapeutics Inc stock worth over $1,146,489 and over the last 7 years she sold PTCT stock worth over $2,814,014. In addition, she makes $1,700,120 as Senior Vice President - Finance y Chief Accounting Officer at PTC Therapeutics Inc.
Christine has made over 26 trades of the PTC Therapeutics Inc stock since 2018, according to the Form 4 filled with the SEC. Most recently she sold 318 units of PTCT stock worth $8,666 on 30 January 2024.
The largest trade she's ever made was exercising 31,758 units of PTC Therapeutics Inc stock on 4 November 2020 worth over $983,545. On average, Christine trades about 5,133 units every 69 days since 2017. As of 30 January 2024 she still owns at least 35,528 units of PTC Therapeutics Inc stock.
You can see the complete history of Ms. Utter stock trades at the bottom of the page.
Christine Marie Utter serves as Senior Vice President - Finance, Chief Accounting Officer of the Company. Ms. Utter joined the Company in 2010 as the Assistant Controller and became Senior Vice President, Finance, in January 2017. From 2005 until 2009, Ms. Utter was the Assistant Corporate Controller of Barrier Therapeutics, a pharmaceutical company. Prior to 2005, Ms. Utter held positions as a financial analyst at Engelhard Corporation and as an auditor at both Ernst & Young LLP and Arthur Andersen. Ms. Utter holds a B.S. in accounting from The College of New Jersey, and is a certified public accountant.
As the Senior Vice President - Finance y Chief Accounting Officer of PTC Therapeutics Inc, the total compensation of Christine Utter at PTC Therapeutics Inc is $1,700,120. There are 5 executives at PTC Therapeutics Inc getting paid more, with Stuart Peltz having the highest compensation of $7,759,440.
Christine Utter is 42, she's been the Senior Vice President - Finance y Chief Accounting Officer of PTC Therapeutics Inc since 2019. There are 18 older and 1 younger executives at PTC Therapeutics Inc. The oldest executive at PTC Therapeutics Inc is Dr. Allan Steven Jacobson, 75, who is the Independent Co-Founder, Chairman of Scientific Advisory Board & Director.
Christine's mailing address filed with the SEC is C/O PTC THERAPEUTICS, INC., 100 CORPORATE COURT, SOUTH PLAINFIELD, NJ, 07080.
Over the last 12 years, insiders at PTC Therapeutics Inc have traded over $50,602,930 worth of PTC Therapeutics Inc stock and bought 3,730,934 units worth $57,374,337 . The most active insiders traders include Suisse/ Credit, Adam Koppel y Bioventures Cayman Ltd Hbm. On average, PTC Therapeutics Inc executives and independent directors trade stock every 16 days with the average trade being worth of $888,748. The most recent stock trade was executed by Pierre Gravier on 16 July 2024, trading 2,269 units of PTCT stock currently worth $77,191.
ptc is biopharmaceutical company focused on the discovery and development of orally-administered, proprietary small molecule drugs that target post-transcriptional control processes. while ptc’s discovery programs are directed at targets in multiple therapeutic areas, ptc is focusing particularly on the development and commercialization of treatments for orphan and ultra-orphan disorders. post-transcriptional control processes regulate the rate and timing of protein production and are essential to proper cellular function. ptc’s internally-discovered pipeline addresses multiple therapeutic areas, including neuromuscular disorders, oncology and infectious diseases. for more information on the company, please visit our website www.ptcbio.com.
PTC Therapeutics Inc executives and other stock owners filed with the SEC include: